ACEPODIA BIOTECHNOLOGIES, LIMITED
Update：2026/08/06
Industries
Main Industry
Biotechnology
Main Product/Service
1. ACC (Antibody-Cell Conjugation) technology
2. γδ2 T cell therapy
3. ACE1831
4. ACE2016
5. ACE1708
2. γδ2 T cell therapy
3. ACE1831
4. ACE2016
5. ACE1708
Founded Year
2017
Unified Business No.
66616512
Status
Active
Number of Employees
10
Total Paid-in
Capital
4,600,000,000 (NT$)
Location of Company
Taiwan
, Taipei City
Exit Status
Emerging Stock Exchange(2023)
Information such as company name, company status, responsible person, year of establishment, paid-in capital, and registered address is sourced from the Commercial and Industrial Registration Office of the Ministry of Economic Affairs; listing status includes emerging stock, M&A, and IPO; overseas development is provided by the startup itself.
Notice: This data is compiled from public sources for reference only. We have no direct affiliation with the company and are not their contact person.
Exclusive content for members
Members-only content. Please log in to access.
About the Company
Acepodia is a clinical-stage biotechnology business that is using its proprietary Antibody-Cell Conjugation (ACC) platform technology to produce first-in-class cell treatments to solve gaps in cancer care. Acepodia employs this live-cell compatible chemistry to attach tumor-targeting antibodies directly to a variety of immune cell receptors,enhancing the lock between immune and cancer cells and generating highly specific, potent cell therapies without the need for genetic engineering.
Acepodia is committed to immunotherapeutic strategies against oncology – expanding our research, clinical development, and manufacturing capabilities. Acepodia currently has a broad pipeline portfolio, each targeting a different type of cancer.
Acepodia is committed to immunotherapeutic strategies against oncology – expanding our research, clinical development, and manufacturing capabilities. Acepodia currently has a broad pipeline portfolio, each targeting a different type of cancer.
